Аксамон®

General characteristics. Structure:

Active agent – an ipidakrina of a hydrochloride оногидрат (Аксамон®) 20 mg (in terms of an ipidakrin a hydrochloride);
excipients – лудипресс (lactoses monohydrate of 93%, povidone of 3,5%, кросповидон 3,5%) 65 mg, carboxymethylstarch of sodium of 14 mg, calcium stearate of 1 mg.

Pharmacological properties:

Pharmacodynamics. Reversible inhibitor of cholinesterase. Owing to blockade of potassium channels of membranes of cells and oppression of activity of cholinesterase stimulates neuromuscular transmission and conductivity of impulses in a nervous system. The M - and N-cholinomimetic action possesses. Strengthens action of acetylcholine, serotonin, a histamine and oxytocin on unstriated muscles therefore increases contractility of smooth muscle bodies, including a GIT and bronchial tubes, urezhat ChSS, strengthens secretion of sialadens, sokratitelny activity of a myometrium, a tone of skeletal muscles. Has a promoting effect on TsNS in combination with separate manifestations of sedative action; promotes improvement of learnability and memory.

Pharmacokinetics. It is quickly soaked up from digestive tract. The maximum concentration in a blood plasma is reached in one hour of 40-55% of active agent contacts proteins of a blood plasma. The elimination half-life makes about 40 min. It is metabolized in a liver. Removal is carried out through kidneys (mainly, by canalicular secretion and only 1/3 drugs are emitted by glomerular filtering), and also ekstrarenalno (through digestive tract).

Indications to use:

Diseases of a peripheral nervous system (neuritis, polyneuritis and polyneuropathy, polyradiculopathies, myasthenia and myasthenic syndrome of various etiology); the recovery period of the organic lesions of the central nervous system which are followed by motive disturbances, including bulbar paralyzes and paresis; complex therapy of demyelinating diseases; senile dementia, Alzheimer's disease, encephalopathies of various genesis.

Route of administration and doses:

Inside. Doses and duration of treatment define individually depending on severity of a disease. Diseases of a peripheral nervous system, myasthenia, myasthenic syndrome: 10-20 mg 1-3 times a day. A course of treatment from one to two months. If necessary the course of treatment can be repeated several times with a break between courses in 1-2 months. Alzheimer's disease, encephalopathies, the recovery period of the organic diseases of the central nervous system which are followed by motive disturbances, including bulbar paralyzes and paresis: the daily dose is selected individually, usually on 10-20 mg 2-3 times a day. At demyelinating defeats of a nervous system it is possible to increase a dose to 20-40 mg of 5-6 times a day.
Maximum daily dose of 200 mg. If one of receptions was missed, then in the following reception the usual dose of drug is accepted.

Features of use:

During treatment it is necessary to refrain from driving of the car, and also occupations potentially dangerous types of activity demanding the increased concentration of attention and speed of psychomotor reactions.

Side effects:

The m-holinoretseptorov caused by excitement: hypersalivation, the strengthened sweating, nausea, diarrhea, jaundice, bradycardia, pain in epigastriums, the strengthened allocation of a secret of bronchial tubes, a bronchospasm, spasms, increase in a tone of a uterus. Hypersalivation and bradycardia it is possible to reduce m-holinoblokatorami: atropine, trigeksifenidit (Cyclodolum), a metotsiniya iodide (Methacinum), etc. More rare, after use of higher doses, dizziness, an ataxy, a headache, vomiting, the general weakness, drowsiness, skin reactions (an itch, rash) were observed. In these cases reduce a dose or quickly (for 1-2 days) interrupt administration of drug.

Interaction with other medicines:

Strengthens sedation in a combination with the means oppressing the central nervous system. Action and side effects amplify at combined use with other inhibitors of cholinesterase and m - cholinomimetic means. At patients with a myasthenia the risk of development of cholinergic crisis increases if to apply ипидакрин along with other cholinergic means. The risk of development of bradycardia increases if prior to treatment β-adrenoblockers were applied.......... Weakens the oppressing action on neuromuscular transmission and carrying out excitement on peripheral nerves of local anesthetics, aminoglycosides, chloride potassium. Alcohol strengthens side effects of drug.

Contraindications:

Hypersensitivity to any of drug components, epilepsy, extrapyramidal disturbances with hyperkinesias, stenocardia, the expressed bradycardia, bronchial asthma, mechanical impassability of intestines or urinary tract, vestibular frustration, a peptic ulcer of a stomach or duodenum in aggravation stages, intolerance of a galactose, deficit of lactase or glyukozo-galaktozny malabsorption, pregnancy and the period of a lactation, children's age up to 18 years.
With care at: a peptic ulcer of a stomach and a duodenum in a remission stage, a thyrotoxicosis, disturbances of endocardiac conductivity; obstructive diseases of respiratory system in the anamnesis or at acute respiratory diseases.

Overdose:

Symptoms: a loss of appetite, a bronchospasm, dacryagogue, the strengthened sweating, narrowing of pupils, a nystagmus, strengthening of a vermicular movement of digestive tract, spontaneous defecation and an urination, vomiting, jaundice, bradycardia, disturbance of endocardiac conductivity, arrhythmia, a lowering of arterial pressure, concern, alarm, excitement, sensation of fear, an ataxy, spasms, a coma, disturbances of the speech, drowsiness and the general weakness.
Treatment: a gastric lavage, use of m-holinoblokatorov (atropine, trigeksifenidit (Cyclodolum), a metotsiniya iodide (Methacinum), etc.), symptomatic therapy.

Storage conditions:

Period of validity 3 years. Not to use after the period of validity specified on packaging. In the dry, protected from light place at a temperature not above 25 °C. To store in the place, unavailable to children.

Issue conditions:

According to the recipe

Packaging:

Tablets of 20 mg. On 10 tablets in a blister strip packaging. 5 blister strip packagings together with the application instruction place in a pack from a cardboard.